

Avantium Extraordinary General Meeting of Shareholders

30 September 2026


Disclaimer

This presentation has been prepared by Avantium N.V. (the “Company”). For the purposes of this notice, the presentation that follows (the “Presentation”) shall mean and include the slides that follow, the oral presentation of the slides by the Company, the question-and answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. Some of the statements in this Presentation constitute forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements relate to future events or the Company’s future financial performance. In some cases, forward looking statements can be identified by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. In evaluating these statements, various risk factors should be taken into account. Risk factors may cause actual results to differ materially from any forward-looking statement. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of such statements. The Company is under no duty to update any of the forward-looking statements after the date of this Presentation or to conform such statements to actual results. The information contained in this Presentation is for information purposes only. Avantium’s reported financial results are prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The information does not constitute or form part of, and should not be construed as, an offer to sell or issue, or a solicitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction, and is not for publication or distribution in the US or to persons in the US (within the meaning of Regulation S under the US Securities Act of 1933 (the “Securities Act”)), Canada, Japan, Australia or any other jurisdiction where such distribution or offer is unlawful. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. Subject to certain limited exceptions, neither this Presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the US, its territories or possessions. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. This presentation contains AI-generated images, which are for illustrative purposes only, do not depict real persons, places or events, and should not be relied upon as authentic.

Opening and Agenda Items

1	Opening
2	Business Update H1 2026
3	Amendment to Articles of Association (voting item)
4	Designation of the Management Board to issue ordinary shares up to the statutory maximum of the increased authorised share capital and to limit or exclude pre-emptive rights in respect thereof, from the EGM until the date of the 2027 AGM (voting item)
5	Closing

Business Update H1 2026



Avantium made significant progress over the last 12 months

Completion of FDCA Flagship Plant



1st FDCA batch produced; working toward 1st sales under offtake agreements to commence end of 2026

Commercial momentum



23 offtakes for FDCA Flagship Plant product sales; 17 capacity reservations (totaling >150kta) for license plants product sales, representing product value of €750m per year

Financial discipline



Headcount reduced by 15% since mid-year 2025; continuing to align organizational structure

Portfolio strategic focus



Ray divested, Volta spin-out realized, Parana spin-out progressing

Profitability target



Financial ambition: c.€90m annualized revenue and EBITDA break-even end of 2027

From capex-heavy project to a commercial platform

Transitioning from an R&D,
pre-revenue Company...



FDCA Flagship Plant



Made by Avantium

Commercial inflection:
start of first
commercial sales


Targeting
c.€90m annualized
revenue &
EBITDA break-even

First potential license
plants on-stream

2030 >



Illustrative License Plants




Expected:
End of 2026

End of 2027

...to a commercial
stage Company

FDCA Flagship Plant moving toward 1st production, paving the way for licensing



Status September 2026:

- Commissioning is completed and the start-up of FDCA production in our Flagship Plant is realized, with the first FDCA produced
- For the remainder of 2026, Avantium will focus on a disciplined product qualification and operating program, to ensure its product meets customer specifications, progressing from batch toward continuous operations
- First commercial shipments to customers are expected to commence end of 2026

FDCA Flagship Plant

1st

First-of-a-kind commercial FDCA plant

5kta

Nameplate production capacity, proving technology at scale

€55m

Revenue at full capacity per annum¹

70


People working in a dedicated FSP team




avantium

EGM 30 September 2026

Note: 1) Include sale of humins: a plant-based, carbon-rich by-product produced during the production of FDCA




Momentum through a wide network of committed partners



PEF: the next-generation performance material

Superior barrier properties

PEF vs PET



Distinctive value proposition



20% weight reduction

Less material required for same performance



Longer shelf life

Food waste reduction



Broader applications

Replaces glass, aluminium and PET



Better recyclability

Mono-material; replaces nylon layers

Sustainability benefits



100% bio-based feedstock




Fully recyclable



Up to 88% lower carbon footprint

Marketed as releaf®



Three-pillar licensing strategy to de-risk adoption for future licensees

Validating and de-risking the licensing model for future licensees

1 Commercial

>150kta of cumulative signed capacity reservations for future license plants

= more than one license plant (100kta)

Signed capacity reservations:



· 8 undisclosed companies

2 Technology

Derisking technology risk by proving commercial-scale production in the FDCA Flagship Plant




3 Feedstock

Ensuring feedstock flexibility through a 1st and 2nd generation sourcing strategy




Strong capacity-backed licensing momentum

Growing number of capacity reservations for future plants...



...supports active engagement with potential licensees



Avantium made significant progress over the last 12 months

Completion of FDCA Flagship Plant



1st FDCA batch produced; working toward 1st sales under offtake agreements to commence end of 2026

Commercial momentum



23 offtakes for FDCA Flagship Plant product sales; 17 capacity reservations (totaling >150kta) for license plants product sales, representing product value of €750m per year

Financial discipline



Headcount reduced by 15% since mid-year 2025; continuing to align organizational structure

Portfolio strategic focus



Ray divested, Volta spin-out realized, Parana spin-out progressing


Profitability target



Financial ambition: c.€90m annualized revenue and EBITDA break-even end of 2027


Financial highlights 1H 2026 (€ millions)

Revenues




■ 1H25 ■ 1H26

EBITDA



■ 1H25 ■ 1H26

Investments




■ 1H25 ■ 1H26

Other income (grants)




■ 1H25 ■ 1H26

Cash




■ FY25 ■ 1H26

Borrowings



■ FY25 ■ 1H26


Cash flows 1H 2026 (€ millions)



We continue to make progress with our spin-offs and divestments

	Non-core businesses	Update
☒	Ray Technology	Sold: announced in May 2026
☒	Volta Technology	Spun-out into NewCo (Carbeau): announced in July 2026
☒	Dawn Technology	Shelved for the foreseeable future: announced in August 2026
☒	Parana	Spin-out: in final stages
☐	R&D Solutions	The Company also continues to evaluate strategic alternatives for Avantium R&D Solutions, including potential partnerships, restructuring initiatives and other options aimed at maximizing value and strengthening its strategic positioning.

Total headcount decreased by ~15% (from ~284 to ~240 FTEs) between mid-2025 and mid-2026, reflecting the company-wide reorganization and the ongoing divestment actions aligning the organization with its strategic priorities.



Questions?

3. Amendment to Articles of Association (voting item)

Current text:

Article 4. Authorised capital.

- 4.1 The authorised capital of the Company equals forty-three million four hundred eighty thousand and sixty euro (EUR 43,480,060).
- 4.2 The authorised capital of the Company is divided into forty-three million four hundred eighty thousand and sixty (43,480,060) Shares, with a nominal value of one euro (EUR 1) each.
- 4.3 All Shares are to be registered Shares. No share certificates (aandeelbewijzen) shall be issued.

Proposed new text:

Article 4. Authorised capital.

- 4.1 The authorised capital of the Company equals one hundred twenty-five million euro (EUR 125,000,000).
- 4.2 The authorised capital of the Company is divided into one hundred twenty-five million (125,000,000) Shares, with a nominal value of one euro (EUR 1) each.
- 4.3 All Shares are to be registered Shares. No share certificates (aandeelbewijzen) shall be issued.



Questions?

Proxy voting results Amendment Articles of Association

For	Against	Abstained
7,295,549	17,923	19,305

4. Designation of the Management Board to issue ordinary shares up to the statutory maximum of the authorised share capital, and to limit or exclude preemptive rights in respect thereof, for the period from the EGM until the date of Avantium's Annual General Meeting to be held in 2027 (*voting item*)



Questions?

Proxy voting results Designation of the Management Board to issue ordinary shares

For	Against	Abstained
7,288,537	25,565	18,675



Closing

Thank you!